Apogee Therapeutics (APGE) Cash from Financing Activities (2022 - 2026)

Apogee Therapeutics (APGE) has 5 years of Cash from Financing Activities data on file, last reported at $411.2 million in Q1 2026.

• On a quarterly basis, Cash from Financing Activities rose 66004.02% year-over-year to $411.2 million in Q1 2026; TTM through Mar 2026 was $807.0 million, a 1685.04% increase from a year earlier, with the FY2025 full-year figure at $396.5 million, down 19.92% from the prior year.
• Cash from Financing Activities for Q1 2026 stood at $411.2 million, up from $375.0 million in the prior quarter.
• Over the last five years, Cash from Financing Activities for APGE reached as high as $450.5 million in Q1 2024 and fell as low as -$213000.0 in Q4 2023.
• Historically, Cash from Financing Activities has averaged $137.2 million across 5 years, with a median of $19.7 million in 2025.
• Across the five-year window, Cash from Financing Activities slumped 100.13% in 2023 and surged 66004.02% in 2026, its largest moves.
• Year by year, Cash from Financing Activities stood at $158.5 million in 2022, then sank by 100.13% to -$213000.0 in 2023, then soared by 20924.41% to $44.4 million in 2024, then surged by 745.32% to $375.0 million in 2025, then increased by 9.66% to $411.2 million in 2026.
• Per Business Quant data, the three most recent Cash from Financing Activities figures were $411.2 million in Q1 2026, $375.0 million in Q4 2025, and $19.7 million in Q3 2025.